H Chen1, L Weng. 1. Ningbo Municipal Liver Diseases Hospital, Zhejiang (315010).
Abstract
OBJECTIVE: To observe the efficacy of Astragalus-Polygonum Anti-Fibrosis Decoction (APAFD) and Jinshuibao capsule (JSBC) in treating liver fibrosis of chronic hepatitis B. METHODS:Ninety-two liver fibrosis of chronic hepatitis B patients were randomly divided into group A and B. Patients in group A received APAFD for 48 weeks, and in group B, they received JSBC for 48 weeks. The effects were observed on the change of hyaluronic acid (HA), laminin (LN), pro-collagen III (PCIII) and collagen IV (CIV) as well as liver functional tests and liver biochemical parameters before and after treatment. RESULTS:Levels of serum HA, LN, PCIII and CIV in the group A declined more obviously than that of group B, the difference was significant (P < 0.01). The liver functional tests such as total bilirubin (TB), alanine aminotransferase (ALT), albumin/globulin ratio, hepatitis related serum biochemical parameters such as cholylglycine (CG), serum ferritin (SF), prealbumin (PA) of group A all were improved more significantly than that of group B (P < 0.01). CONCLUSION:APAFD is more effective than JSBC in treating liver fibrosis of chronic hepatitis B, and in the inhibition of hepatic inflammation, it is a good composite Chinese herbal preparation against liver fibrosis.
RCT Entities:
OBJECTIVE: To observe the efficacy of Astragalus-Polygonum Anti-Fibrosis Decoction (APAFD) and Jinshuibao capsule (JSBC) in treating liver fibrosis of chronic hepatitis B. METHODS: Ninety-two liver fibrosis of chronic hepatitis Bpatients were randomly divided into group A and B. Patients in group A received APAFD for 48 weeks, and in group B, they received JSBC for 48 weeks. The effects were observed on the change of hyaluronic acid (HA), laminin (LN), pro-collagen III (PCIII) and collagen IV (CIV) as well as liver functional tests and liver biochemical parameters before and after treatment. RESULTS: Levels of serum HA, LN, PCIII and CIV in the group A declined more obviously than that of group B, the difference was significant (P < 0.01). The liver functional tests such as total bilirubin (TB), alanine aminotransferase (ALT), albumin/globulin ratio, hepatitis related serum biochemical parameters such as cholylglycine (CG), serum ferritin (SF), prealbumin (PA) of group A all were improved more significantly than that of group B (P < 0.01). CONCLUSION:APAFD is more effective than JSBC in treating liver fibrosis of chronic hepatitis B, and in the inhibition of hepatic inflammation, it is a good composite Chinese herbal preparation against liver fibrosis.